In order to investigate the antiyhypertensive effect and the safety of oral perindopril, long acting angiotensin converting enzyne inhibitor, daily doses of 4 to 8 mg once a day were administered in 20 essential hypertensive patients whose
diastolic
blood pressures were between 95-115 mmHg. Blood pressure and pulse rate were measured every 2 weeks. The complete blood count with patelet count blood cyhemistry by SMA-12 including serum electrolytes and urinalysis were performed before the
treatment
an at the 6th week, and 12th week of therapy. Any kinds of side effects were actively questioned by physifcians. The results are as follows:
1) The mean age was 49.2 years, and the male female ratio was 9:11.
2) Blood pressure fell significantly in 2 weeks of treatment with pe4ridopril (M±S.DD., 156.0±16.7 vs 131.8±10.9, 102.8±4.7 vs 84.3±7.5, p<0.05), and during 12 weeks of the teatment with perindopril, statistically significant blood pressure
changes were maintained.
3) There were no significant changes in pulse rate (72.4±4.8 vs 71.0±6.3, p>0.05) and body weight (63.1±13.9 vs 66.1±4.6, p>0.05) during 12 weeks of treatment with peridopril.
4) There were no significant changes in blood chemistry including blood urea nitrogen, serum creatinin, blood sugar, transaminase, uric acid, cholesterol, and electrolyte.
5) There were no statistical differences in hematologic findings, but amounts of urinary protein were significantly decreased (p<0.05) at 12 weeks of treatment.
6) Total 5 patients (25%) had various side effects: cough (15%), headache (10%), constipation (5%), indigestion (5%), which were not so severe to discontinue perindopril.
On conclusion, perindopril in dose of 4 to 8 mg once a day was effective in hypertension control and well tolerated in most cases without severe side effects in essential hypertensive patients with diastolic blood pressure between 95 and 115
mmHg.
|